Trial · NCT00525525
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
NCT00525525, Phase 2, Completed, University of California, San Francisco; results first posted 2014-11-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma. Trials, record NCT00525525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00525525
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
- NCT number
- NCT00525525
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 74 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab, Tarceva, Temozolomide
- First posted
- 2007-09-05
- Last updated
- 2014-11-14
- Results first posted
- 2014-11-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | Approximately 6-24 months | Overall survival was defined from the date of diagnosis to date of death from any cause |
| Primary | Unexpected Toxicities During First 2 Cycles of Study Drug | Within 8 weeks of initiating study therapy | Unexpected severe study-related adverse events |
| Secondary | Progression-free Survival | Approximately 6 months to 1 year | Progression-free survival was defined from the date of diagnosis to the date that progressive disease was first observed on imaging, or the date at which nonreversible neurologic progression or permanently increased corticosteroid requirement, death from any cause, or early discontinuation of treatment. Imaging guidelines were used to evaluate progression: (i) 25% increase in the sum of products of all measurable lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline; (ii) clear worsening of any assessable disease; (iii) appearance of any new lesion/site; and (iv) clear clinical worsening or failure to return for evaluation as a result of death or deteriorating condition (unless clearly unrelated to this cancer). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) | Approximately 6-24 months | months | MEDIAN | |
| SECONDARY | Progression-free Survival | Approximately 6 months to 1 year | months | MEDIAN | |
| PRIMARY | Unexpected Toxicities During First 2 Cycles of Study Drug | Within 8 weeks of initiating study therapy | Events | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Efficacy Group | 19.8 | 95% Confidence Interval 17.1 to 28.6 | months | |
| Progression-free Survival | Efficacy Group | 13.5 | 95% Confidence Interval 12.2 to 17 | months | |
| Unexpected Toxicities During First 2 Cycles of Study Drug | Safety Lead-in Group | 0 | Events |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Efficacy Group | 59 | |
| Overall Study | STARTED | Safety Lead-in Group | 15 | |
| Overall Study | COMPLETED | Efficacy Group | 59 | |
| Overall Study | COMPLETED | Safety Lead-in Group | 15 | |
| Overall Study | NOT COMPLETED | Efficacy Group | 0 | |
| Overall Study | NOT COMPLETED | Safety Lead-in Group | 0 |
Source ClinicalTrials.gov
Adverse events102
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Efficacy Group | 5 | 59 | |
| other | Diarrhea | Gastrointestinal disorders | Safety Lead-in Group | 2 | 15 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Efficacy Group | 7 | 59 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Safety Lead-in Group | 1 | 15 | |
| other | Leukocytes | Blood and lymphatic system disorders | Efficacy Group | 11 | 59 | |
| other | Leukocytes | Blood and lymphatic system disorders | Safety Lead-in Group | 2 | 15 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Efficacy Group | 39 | 59 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Safety Lead-in Group | 8 | 15 | |
| other | Neutrophils/granulocytes (ANC/AGC) | Blood and lymphatic system disorders | Efficacy Group | 6 | 59 | |
| other | Neutrophils/granulocytes (ANC/AGC) | Blood and lymphatic system disorders | Safety Lead-in Group | 2 | 15 |
1 to 10 of 102Source ClinicalTrials.gov
See all 102 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Efficacy Group | ||
| Total, all-cause mortality | Safety Lead-in Group | ||
| Total, other adverse events | Efficacy Group | 53 | 59 |
| Total, other adverse events | Safety Lead-in Group | 14 | 15 |
| Total, serious adverse events | Efficacy Group | 32 | 59 |
| Total, serious adverse events | Safety Lead-in Group | 7 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24637230 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Efficacy Group vs Safety Lead-in Group: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00525525
GET https://conductscience.org/api/trials/v1/NCT00525525/events?page=2